Bruker Corporation $BRKR Shares Bought by Cwm LLC

Cwm LLC increased its holdings in Bruker Corporation (NASDAQ:BRKR) by 30.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 56,931 shares of the medical research company’s stock after buying an additional 13,335 shares during the quarter. Cwm LLC’s holdings in Bruker were worth $2,346,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Pinnacle Bancorp Inc. acquired a new position in Bruker in the 1st quarter worth approximately $29,000. Allworth Financial LP increased its holdings in Bruker by 92.4% in the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock worth $30,000 after buying an additional 364 shares during the period. Caitong International Asset Management Co. Ltd increased its holdings in Bruker by 1,354.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock worth $33,000 after buying an additional 745 shares during the period. Parallel Advisors LLC increased its holdings in Bruker by 63.0% in the 2nd quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock worth $37,000 after buying an additional 347 shares during the period. Finally, Annis Gardner Whiting Capital Advisors LLC acquired a new position in Bruker in the 1st quarter worth approximately $42,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Trading Down 3.2%

Shares of NASDAQ:BRKR opened at $36.98 on Friday. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $64.64. The firm has a market capitalization of $5.61 billion, a price-to-earnings ratio of 71.12, a price-to-earnings-growth ratio of 5.18 and a beta of 1.20. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. The business’s 50 day moving average price is $33.48 and its 200-day moving average price is $36.98.

Bruker (NASDAQ:BRKR) last announced its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business had revenue of $797.40 million for the quarter, compared to analysts’ expectations of $811.17 million. During the same quarter last year, the business earned $0.52 EPS. The company’s quarterly revenue was down .4% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, equities research analysts forecast that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd were given a dividend of $0.05 per share. The ex-dividend date was Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. Bruker’s dividend payout ratio (DPR) is 38.46%.

Analysts Set New Price Targets

Several brokerages recently weighed in on BRKR. Stifel Nicolaus set a $40.00 price target on shares of Bruker and gave the stock a “hold” rating in a report on Tuesday, August 5th. Barclays lowered their price objective on Bruker from $43.00 to $40.00 and set an “overweight” rating on the stock in a research report on Thursday, October 2nd. Bank of America lowered their price objective on Bruker from $61.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, June 26th. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a research report on Wednesday, October 8th. Finally, Citigroup lowered their price objective on Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a research report on Monday, August 4th. Five investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Bruker currently has an average rating of “Hold” and an average price target of $51.00.

Insider Activity

In other news, Director Cynthia M. Friend sold 3,535 shares of the stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the transaction, the director owned 18,016 shares in the company, valued at $581,016. This trade represents a 16.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 27.30% of the stock is owned by company insiders.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.